Status:

UNKNOWN

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

Lead Sponsor:

Craig L Slingluff, Jr

Conditions:

Pancreatic Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of this clinical trial is to study an experimental drug called pembrolizumab or MK-3475 for use in combination with chemotherapy and radiation therapy for patients with resectable (surgica...

Eligibility Criteria

Inclusion

  • Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.
  • Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale
  • Adequate organ function
  • In subjects requiring biliary decompression, metal stent or drainage using percutaneous transhepatic cholangiogram (PTC) are allowed

Exclusion

  • Immunodeficiency or taking steroid or any other form of immunosuppressive therapy
  • Has a plastic biliary stent for decompression
  • Metastatic disease
  • Prior treatment for pancreatic cancer (other than 4-8 cycles of Folfirinox) or prior treatment with radiation for other diagnoses to the expected pancreatic cancer treatment area
  • Active autoimmune disease
  • Pregnancy or Nursing
  • Known history of Human Immunodeficiency Virus (HIV) or Hepatitis B or C
  • Prior monoclonal antibody within 4 weeks prior to study Day 1
  • Known additional malignancy that is progressing or requires active treatment
  • Evidence of interstitial lung disease or active, non-infectious pneumonitis
  • Active infection requiring systemic therapy
  • Prior therapy with an anti-Program Death (PD-1) antibody, anti-PD-L1, anti-PD-L2, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody

Key Trial Info

Start Date :

March 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2022

Estimated Enrollment :

68 Patients enrolled

Trial Details

Trial ID

NCT02305186

Start Date

March 1 2015

End Date

December 1 2022

Last Update

August 13 2021

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Mayo Clinic Cancer Center

Phoenix, Arizona, United States, 85054

2

Hartford HealthCare

Hartford, Connecticut, United States, 06102

3

University of Miami

Miami, Florida, United States, 33136

4

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215